Portola Pharmaceuticals Inc. diskutieren
Portola Pharmaceuticals Inc.
WKN: A1T9FK / Symbol: PTLA / Name: Portola Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
Portola's two approved drugs are targeting significant markets:
The most important of these is Andexxa.
This compound is targeted at being a "universal antidote" for the new breed of anticoagulants like Eliquis. This is something the industry has desperately needed for some time, as more than 80,000 individuals end up in the emergency room annually in the United States due to negative reactions to these medications, many of them life threatening. Andexxa was just approved in May of this year and is just being rolled out. The second generation Andexxa should be approved at yearend. The first
generation is only being marketed to select hospitals. Approval of the second generation Andexxa will kick manufacturing and marketing of Andexxa into overdrive.
The other compound in Portola's product portfolio is Bevyxxa or betrixaban which was approved for Venous thromboembolism (VTE) Prevention in the early summer of 2017. To be more specific, Bevyxxa is the only FDA approved drug for VTE in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complication due to moderate or severe restricted mobility and other risk factors for VTE.
The company has another promising compound 'Cerdulatinib' in development. Cerdulatinib has been granted the Orphan Drug Designation by the FDA for the treatment of peripheral T-cell lymphoma. A pivotal trial for this condition should kick off in the first quarter of next year. Updated Phase 2 data for the treatment of refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer will be presented at the big American Society of Hematology or ASH conference on December 3rd.
marge stimmt der Buy-Einschätzung von stratec zu
marge stimmt am 01.01.2019 der Buy-Einschätzung von stratec mit dem Kursziel 38$ zu.
Überschrift: Portola's two approved drugs are targeting significant markets:
tamam stimmt der Outperform-Einschätzung der institutionellen Analysten zu
tamam stimmt am 03.01.2019 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 35.83$ zu.
Portola Pharma
Krass
stark bei negativem Markt.
geldnutzer stimmt dem Sentiment von 'Buy' zu
geldnutzer stimmt am 10.03.2019 dem Buy-Gesamtsentiment mit dem Kursziel 46.5$ zu.
Secteur Recherche biotechnologique et médicale Agenda 06/05 Publication de résultats
Neueste Beiträge
Traumtanz in Ballard Power Systems diskutieren, Ballard Power Systems Inc.